Ruth Merkatz

Clinical Development

With a background in nursing, Ruth Merkatz has always been focused on women’s health.

Today, she continues to focus on understanding the needs of women and helping to design and develop technologies that give them choice in and control over their health. Ruth oversees development of the Council’s reproductive health products and large-scale clinical trials. She ran the phase three clinical program of the Council’s one-year vaginal contraceptive system, Annovera™, approved by the U.S. FDA in August 2018.  Annovera, a soft, flexible ring, is the first and only contraceptive method to provide an entire year of protection against unintended pregnancy while fully under a woman’s control.

Women’s needs aren’t all the same, and they need different contraceptive methods at different times in their life. That’s why Ruth remains so dedicated to her work to develop and bring innovative products to women around the world.

The Nestorone®/Ethinyl Estradiol One-Year Vaginal Contraceptive System

Council researchers have developed a long-acting contraceptive vaginal system approved by the FDA that can prevent pregnancy for one full year.